Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 1/20 | 0.82 |
| ▸ | MTOR | P42345 | 1/20 | 0.82 |
| ▸ | GMNN | O75496 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | BLM | P54132 | 1/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.80 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12087892 | 1.00 | UGCG (1.00) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL7677086 | 1.00 | UGCG (1.00) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL31275968 | 1.00 | UGCG (1.00) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL13398086 | 1.00 | UGCG (1.00) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL13567769 | 1.00 | UGCG (1.00) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL23845861 | 1.00 | UGCG (1.00) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL7101172 | 1.00 | UGCG (1.00) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL7797129 | 0.99 | UGCG (0.98) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL3863329 | 0.99 | UGCG (0.98) | UGCGMEN1KMT2ATP53CYP3A4 | |
| SCHEMBL13567767 | 0.99 | UGCG (0.98) | UGCGMEN1KMT2ATP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583860-A1 | INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOR OVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-07-16 | — | — | EP | claimed |
| WO-2024052356-A1 | INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOR OVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-14 | — | — | WO | claimed |
| US-20220257604-A1 | COMPOSITIONS AND METHODS FOR MODULATING VIRAL INFECTIONS BY REGULATING GLUCOSYLCERAMIDES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-18 | — | — | US | claimed |
| US-20220062254-A1 | INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES | ICM INST DU CERVEAU ET DE LA MOELLE EPINIERE (FR) | 2022-03-03 | — | — | US | claimed |
| EP-3934688-A1 | COMPOSITIONS AND METHODS FOR MODULATING VIRAL INFECTIONS BY REGULATING GLUCOSYLCERAMIDES | University of Virginia Patent Foundation (US) | 2022-01-12 | — | — | EP | claimed |
| US-11065238-B2 | Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2021-07-20 | — | — | US | claimed |
| WO-2020185675-A1 | COMPOSITIONS AND METHODS FOR MODULATING VIRAL INFECTIONS BY REGULATING GLUCOSYLCERAMIDES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-09-17 | — | — | WO | claimed |
| US-20190350913-A1 | INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2019-11-21 | — | — | US | claimed |
| EP-3534958-A1 | INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES | ICM - Institut du Cerveau et da la Moelle Epinière (FR) | 2019-09-11 | — | — | EP | claimed |
| EP-3318277-A1 | INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE FOR THE TREATMENT OF MOTOR NEURON DISEASES | Institut du Cerveau et de la Moelle Epiniere-ICM (FR) | 2018-05-09 | — | — | EP | claimed |
| WO-2001054654-A2 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| US-6235737-B1 | APPLYING COMPOUND TO ADJUST CERAMIDE CONCENTRATION | GILLETTE COMPANY, THE | 2001-05-22 | — | — | US | claimed |
| EP-0996433-A1 | METHODS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH LACTOSYLCERAMIDE | THE JOHNS HOPKINS UNIVERSITY (US) | 2000-05-03 | — | — | EP | claimed |
| US-6051598-A | TREATING A PATIENT HAVING SPHINGOLIPIDOSIS BY REDUCING GLYCOSPHINGOLIPID SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2000-04-18 | — | — | US | claimed |
| US-6040332-A | INHIBIT GLUCOSYL CERAMIDE (GLCCER) FORMATION BY INHIBITING THE ENZYME GLCCER SYNTHASE, THEREBY LOWERING THE LEVEL OF GLYCOSPHINGOLIPIDS. | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2000-03-21 | — | — | US | claimed |
| US-6030995-A | 1-PYRROLIDINO-2-FATTY CARBOXYAMIDO-3-HYDROXY-3-ALKYL- OR ARYLPROPANES; INHIBITORS OF THE GLUCOSYL CERAMIDE SYNTHETASE, THEREBY LOWERING THE LEVEL OF GLYCOSPHINGOLIPIDS; METABOLIC DISORDERS, E.G., TAY-SACHS, GAUCHER'S AND FABRY'S DISEASES, | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2000-02-29 | — | — | US | claimed |
| US-5952370-A | ADMINISTERING A 1-ALKYL OR ARYL OR ALICYCLIC-2-ALKYLOYLAMINO-3-PYRROLIDINO-1-PROPANOL DERIVATIVE TO TREAT CONDITION OR DISEASES ASSOCIATED WITH GLYCOSYL CERAMIDE FORMATION; ENZYME INHIBITOR | THE REGENTS OF UNIVERSITY OF MICHIGAN (US) | 1999-09-14 | — | — | US | claimed |
| US-5945442-A | Amino ceramide-like compounds and therapeutic methods of use | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1999-08-31 | — | — | US | claimed |
| US-5916911-A | ANTITUMOR | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1999-06-29 | — | — | US | claimed |
| WO-1997010817-A1 | AMINO CERAMIDE-LIKE COMPOUNDS AND THERAPEUTIC METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1997-03-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065238-B2 | Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases | GBA1, SMN1; SMN2, GAA | UGCG 13/4885MEN1 3980/4885KMT2A 2710/4885 |
| US-20190350913-A1 | INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES | GBA1, SMN1; SMN2, GAA | UGCG 13/4885MEN1 3980/4885KMT2A 2710/4885 |
| US-20220062254-A1 | INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES | GBA1, SMN1; SMN2, GAA | UGCG 13/4885MEN1 3980/4885KMT2A 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.